{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:25:51Z","timestamp":1786962351367,"version":"build-2736575974"},"reference-count":101,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Personalized cancer treatments help to deliver tailored and biologically driven therapies for cancer patients. Interventional oncology techniques are able to treat malignancies in a locoregional fashion, with a variety of mechanisms of action leading to tumor necrosis. Tumor destruction determines a great availability of tumor antigens that can be recognized by the immune system, potentially triggering an immune response. The advent of immunotherapy in cancer care, with the introduction of specific immune checkpoint inhibitors, has led to the investigation of the synergy of these drugs when used in combination with interventional oncology treatments. The aim of this paper is to review the most recent advances in the field of interventional oncology locoregional treatments and their interactions with immunotherapy.<\/jats:p>","DOI":"10.3390\/ijms24087344","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T03:14:09Z","timestamp":1681701249000},"page":"7344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-3413","authenticated-orcid":false,"given":"Alessandro","family":"Posa","sequence":"first","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Contegiacomo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-6238","authenticated-orcid":false,"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology-Hepatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-0985","authenticated-orcid":false,"given":"Ernesto","family":"Punzi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mazza","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2500-5110","authenticated-orcid":false,"given":"Annarita","family":"Scrofani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology-Hepatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2940-9822","authenticated-orcid":false,"given":"Shraga Nahum","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Image-Guided Therapy, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem 12000, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-5119","authenticated-orcid":false,"given":"Luigi","family":"Natale","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6230-1779","authenticated-orcid":false,"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology-Hepatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evis","family":"Sala","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy"},{"name":"Facolt\u00e0 di Medicina e Chirurgia, Universit\u00e0 Cattolica del Sacro Cuore, L.go F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1148\/radiol.2019182326","article-title":"Immunotherapy and the Interventional Oncologist: Challenges and Opportunities\u2014A Society of Interventional Oncology White Paper","volume":"292","author":"Erinjeri","year":"2019","journal-title":"Radiology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20200112","DOI":"10.1259\/bjr.20200112","article-title":"The evolution of interventional oncology in the 21st century","volume":"93","author":"Helmberger","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system: The 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JU.0000000000001912","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II","volume":"206","author":"Campbell","year":"2021","journal-title":"J. Urol."},{"key":"ref_6","first-page":"5343","article-title":"Immuno-oncology and interventional oncology: A winning combination. The latest scientific evidence","volume":"23","author":"Lucatelli","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.lpm.2019.06.005","article-title":"Percutaneous image-guided ablation: From techniques to treatments","volume":"48","author":"Ridouani","year":"2019","journal-title":"Presse Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","article-title":"Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma","volume":"70","author":"Leuchte","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11912-020-00943-6","article-title":"Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma","volume":"22","author":"Zeng","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jvir.2017.07.018","article-title":"Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures","volume":"28","author":"Hickey","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00270-016-1531-y","article-title":"CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma","volume":"40","author":"Krokidis","year":"2016","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00270-012-0340-1","article-title":"Standards of Practice: Guidelines for Thermal Ablation of Primary and Secondary Lung Tumors","volume":"35","author":"Pereira","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00270-009-9738-9","article-title":"Quality Improvement Guidelines for Bone Tumour Management","volume":"33","author":"Gangi","year":"2010","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.21037\/tlcr-20-1075","article-title":"Thermal ablation in non-small cell lung cancer: A review of treatment modalities and the evidence for combination with immune checkpoint inhibitors","volume":"10","author":"Rangamuwa","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40880-017-0216-5","article-title":"Immunological effect of local ablation combined with immunotherapy on solid malignancies","volume":"36","author":"Takahashi","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156652408784221306","article-title":"Molecular Mechanisms and Pathophysiology of Necrotic Cell Death","volume":"8","author":"Vanlangenakker","year":"2008","journal-title":"Curr. Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1158\/0008-5472.CAN-03-3949","article-title":"In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity","volume":"64","author":"Brok","year":"2004","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00262-016-1858-x","article-title":"Optimized magnitude of cryosurgery facilitating anti-tumor immunoreaction in a mouse model of Lewis lung cancer","volume":"65","author":"Takahashi","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molimm.2017.10.003","article-title":"Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer","volume":"92","author":"Liang","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A Pilot Study of Preoperative Single-Dose Ipilimumab and\/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0b013e31818df785","article-title":"Combined Cryoablation and GM-CSF Treatment for Metastatic Hormone Refractory Prostate Cancer","volume":"32","author":"Si","year":"2009","journal-title":"J. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cryobiol.2013.08.001","article-title":"Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer","volume":"67","author":"Yuanying","year":"2013","journal-title":"Cryobiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3748\/wjg.v19.i22.3473","article-title":"Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer","volume":"19","author":"Niu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/MPA.0b013e3182965dde","article-title":"Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer","volume":"42","author":"Niu","year":"2013","journal-title":"Pancreas"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41391-018-0035-z","article-title":"Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer","volume":"21","author":"Benzon","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.12659\/MSM.898194","article-title":"The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model","volume":"22","author":"Zhang","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/WNR.0000000000000196","article-title":"In-situ administration of dendritic cells following argon\u2013helium cryosurgery enhances specific antiglioma immunity in mice","volume":"25","author":"Lin","year":"2014","journal-title":"Neuroreport"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4149\/neo_2014_081","article-title":"Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model","volume":"61","author":"Li","year":"2014","journal-title":"Neoplasma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00262-014-1520-4","article-title":"Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity","volume":"63","author":"Alteber","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1158\/1078-0432.CCR-04-2422","article-title":"Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity","volume":"11","author":"Machlenkin","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/WNR.0000000000000351","article-title":"Synergism between cryoablation and GM-CSF: Enhanced immune function of splenic dendritic cells in mice with glioma","volume":"26","author":"Xu","year":"2015","journal-title":"Neuroreport"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1158\/0008-5472.CAN-06-0206","article-title":"Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine","volume":"66","author":"Brok","year":"2006","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/0008-5472.CAN-11-1782","article-title":"Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti\u2013CTLA-4 Therapy","volume":"72","author":"Waitz","year":"2012","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1148\/radiol.13120249","article-title":"Radiofrequency Ablation and Immunostimulant OK-432: Combination Therapy Enhances Systemic Antitumor Immunity for Treatment of VX2 Lung Tumors in Rabbits","volume":"267","author":"Hamamoto","year":"2013","journal-title":"Radiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0024-3","article-title":"Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis","volume":"114","author":"Habibi","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diii.2017.12.011","article-title":"Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model","volume":"99","author":"Zhu","year":"2018","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/02656730500052027","article-title":"Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: Induction of potent anti-residual tumour immunity","volume":"21","author":"Kuang","year":"2005","journal-title":"Int. J. Hyperth."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Vanagas, T., Gulbinas, A., Pundzius, J., and Barauskas, G. (2010). Radiofrequency ablation of liver tumors (I): Biological background. Medicina, 46.","DOI":"10.3390\/medicina46010002"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40425-017-0284-8","article-title":"Immuno-thermal ablations\u2014Boosting the anticancer immune response","volume":"5","author":"Slovak","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1053\/j.semtcvs.2016.02.008","article-title":"Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer","volume":"28","author":"Schneider","year":"2016","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26153","article-title":"Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma","volume":"57","author":"Mizukoshi","year":"2012","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12013-014-0262-4","article-title":"Effectiveness of Combined 131I-chTNT and Radiofrequency Ablation Therapy in Treating Advanced Hepatocellular Carcinoma","volume":"71","author":"Tu","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3748\/wjg.v26.i17.2040","article-title":"Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations","volume":"26","author":"Sodergren","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gameiro, S.R., Higgins, J.P., Dreher, M.R., Woods, D.L., Reddy, G., Wood, B.J., Guha, C., and Hodge, J.W. (2013). Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070417"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00262-013-1514-7","article-title":"In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation","volume":"63","author":"Nakagawa","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1148\/radiol.2015150080","article-title":"Hepatic Radiofrequency Ablation\u2013induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition","volume":"279","author":"Ahmed","year":"2016","journal-title":"Radiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/tomography7040057","article-title":"Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms","volume":"7","author":"Iezzi","year":"2021","journal-title":"Tomography"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9251375","DOI":"10.1155\/2016\/9251375","article-title":"Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?","volume":"2016","author":"Mehta","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.copbio.2020.01.006","article-title":"Cryoablation and immunotherapy of cancer","volume":"65","author":"Yakkala","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/02656736.2018.1539253","article-title":"Engineering T cell response to cancer antigens by choice of focal therapeutic conditions","volume":"36","author":"Shao","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cryobiol.2019.01.015","article-title":"PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma","volume":"87","author":"Zhu","year":"2019","journal-title":"Cryobiology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"81967","DOI":"10.18632\/oncotarget.17804","article-title":"Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.imlet.2017.03.004","article-title":"Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer","volume":"184","author":"Lin","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s12026-017-8927-x","article-title":"Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer","volume":"65","author":"Lin","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2019.37.15_suppl.592","article-title":"Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC)","volume":"37","author":"Comen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1148\/radiol.2015151166","article-title":"Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model","volume":"280","author":"Bulvik","year":"2016","journal-title":"Radiology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jvir.2019.02.023","article-title":"Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma","volume":"30","author":"Vivas","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1159\/000492509","article-title":"Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome","volume":"48","author":"Alnaggar","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00270-018-2069-y","article-title":"Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer","volume":"42","author":"Yang","year":"2018","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11912-021-01057-3","article-title":"Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy","volume":"23","author":"Timmer","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/2326-6066.CIR-19-0101","article-title":"Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model","volume":"7","author":"Narayanan","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.18632\/oncotarget.21974","article-title":"An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_67","first-page":"1643","article-title":"Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer","volume":"25","author":"Pan","year":"2020","journal-title":"J. BUON"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"160250","DOI":"10.1155\/2011\/160250","article-title":"More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer","volume":"2011","author":"Haen","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/02656730902976807","article-title":"Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model","volume":"25","author":"Chen","year":"2009","journal-title":"Int. J. Hyperth."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3892\/etm.2015.2681","article-title":"Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation","volume":"10","author":"Yu","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4161\/cbt.11.5.14669","article-title":"Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma","volume":"11","author":"Zhou","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cyto.2006.06.003","article-title":"Early cytokine responses after percutaneous magnetic resonance imaging guided laser thermoablation of malignant liver tumors","volume":"34","author":"Kallio","year":"2006","journal-title":"Cytokine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00262-009-0663-1","article-title":"Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases","volume":"58","author":"Vogl","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3748\/wjg.v22.i6.1935","article-title":"Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art","volume":"22","author":"Iezzi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.dld.2014.12.007","article-title":"Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma","volume":"47","author":"Iezzi","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"Volume 19","author":"Llovet","year":"1999","journal-title":"Seminars in Liver Disease"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236. Erratum in J. Hepatol.2019, 70, 817.","DOI":"10.1016\/j.jhep.2019.01.020"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00270-020-02646-8","article-title":"The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis","volume":"44","author":"Pereira","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","article-title":"Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations","volume":"35","author":"Lencioni","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4049\/jimmunol.178.3.1914","article-title":"Unmasking of \u03b1-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization","volume":"178","author":"Ayaru","year":"2007","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liao, Y., Wang, B., Huang, Z.-L., Shi, M., Yu, X.-J., Zheng, L., Li, S., and Li, L. (2013). Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060444"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/15384047.2018.1433501","article-title":"A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE","volume":"19","author":"Zhang","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00428-016-2051-5","article-title":"CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia","volume":"470","author":"Semaan","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1200\/jco.2015.33.15_suppl.4081","article-title":"A pilot study of tremelimumab\u2014A monoclonal antibody against CTLA-4\u2014In combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC)","volume":"33","author":"Duffy","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26382","article-title":"Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives","volume":"58","author":"Salem","year":"2013","journal-title":"Hepatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s00270-022-03187-y","article-title":"Holmium-166 Radioembolization: Current Status and Future Prospective","volume":"45","author":"Stella","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_96","first-page":"4014","article-title":"The ten commandments of hepatic radioembolization: Expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017","volume":"21","author":"Bilbao","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jvir.2009.05.030","article-title":"Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review","volume":"20","author":"Riaz","year":"2009","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2018","journal-title":"Gut"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma","volume":"31","author":"Zhan","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00270-018-1993-1","article-title":"Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","volume":"41","author":"Goyal","year":"2018","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1200\/JCO.2020.38.15_suppl.4590","article-title":"A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678","volume":"38","author":"Tai","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:16:43Z","timestamp":1760123803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":101,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24087344"],"URL":"https:\/\/doi.org\/10.3390\/ijms24087344","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]}}}